Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Raw Materials: 2019-2025

Historic Raw Materials for Ptc Therapeutics (PTCT) over the last 5 years, with Sep 2025 value amounting to $2.2 million.

  • Ptc Therapeutics' Raw Materials fell 18.04% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 18.04%. This contributed to the annual value of $2.5 million for FY2024, which is 166.60% up from last year.
  • Latest data reveals that Ptc Therapeutics reported Raw Materials of $2.2 million as of Q3 2025, which was up 2.51% from $2.2 million recorded in Q2 2025.
  • Ptc Therapeutics' Raw Materials' 5-year high stood at $2.7 million during Q3 2024, with a 5-year trough of $678,000 in Q1 2021.
  • Its 3-year average for Raw Materials is $1.6 million, with a median of $1.1 million in 2024.
  • As far as peak fluctuations go, Ptc Therapeutics' Raw Materials dropped by 26.92% in 2023, and later soared by 201.87% in 2024.
  • Over the past 5 years, Ptc Therapeutics' Raw Materials (Quarterly) stood at $1.4 million in 2021, then declined by 23.98% to $1.1 million in 2022, then decreased by 11.69% to $952,000 in 2023, then surged by 166.60% to $2.5 million in 2024, then dropped by 18.04% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, $2.2 million for Q2 2025, and $2.1 million during Q1 2025.